Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Patients on the twice-daily exenatide were significantly less likely to experience treatment failure than those on the sulfonylurea glimepiride (41% versus 54%, HR 0.75, 95% CI 0.62 to 0.90,P=0.002), Baptist Gallwitz, MD, of Universitatsklinikum Tubingen in Tubingen, Germany, and colleagues reported online in The Lancet and at the American Diabetes Association meeting here
AOD 9604 vs other fat loss peptides You're probably considering other options
Orforglipron (Eli Lilly) Orforglipron is a first-in-class, nonpeptide oral GLP-1 receptor agonist
(2016b)